Company
Proteomics International Laboratories Ltd
ASX:PIQ
Proteomics International Laboratories Ltd is a pioneering medical technology company operating at the forefront of predictive diagnostics and bio-analytical services. The company specialises in proteomics – the industrial scale study of the structure and function of proteins.
37 stories
Proteomics International to collaborate with University of Melbourne and Royal Women’s Hospital to develop a test for endometriosis
The collaboration aims to build on a Proteomics study that identified protein ‘fingerprints’ in the blood - known as biomarkers - that could be used to test for endometriosis.
Proteomics International engages Abcam to manufacture PromarkerD reagents
According to the company, securing a supply agreement with Abcam and implementing other necessary processes are an essential part of its commercialisation strategy aimed at delivering PromarkerD in global markets.
Proteomics International Laboratories secures Indonesian patent for its diagnostic test
Concurrently, TGA regulatory approval granted for PromarkerD software as an in vitro diagnostic for export use.
Proteomics International to present at diabetes conference featuring PromarkerD test
In parallel with the global roll-out of PromarkerD to markets, the company is pursuing registration of the kit version of the test for larger-scale adoption.
Proteomics International Laboratories set to ship first commercial batch of its immunoassay kit
PromarkerD is the world's first commercial test for predicting the onset of diabetic kidney disease.
Proteomics International Laboratories boosts balance sheet with sale of CPR Pharm Services stake
An MOU between the two companies targeting advanced diagnostics and analytical services for clinical trials remains in place.
Proteomics International Laboratories to reveal results
The halt will remain in place until Wednesday 14th June 2017.
Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions
Richard Lipscombe talked revenue generation and growth path with investors.
Proteomics International Laboratories targets first sales in 2017
Prototype manufacture on target for mid-2017, sales end of 2017.
Aspire Mining [JOHN TO UPDATE] Proactive's Spotlight CEO Sessions
Find out more from David Paull at Proactive's CEO Spotlight Sessions.
Dimerix brings Phase II clinical trials to Proactive's Spotlight CEO Sessions
Find out more from Kathy Harrison at Proactive's CEO Spotlight Sessions.
Novogen [JOHN TO UPDATE] at Proactive's Spotlight CEO Sessions
Find out more from Dr James Garner at Proactive's CEO Sessions.
Proteomics International to outline pathway to market at Proactive's CEO Sessions
Find out more from Richard Lipscombe at Proactive's CEO Sessions.
Southern Gold brings gold production to Proactive's Spotlight CEO Sessions
Find out more from Simon Mitchell at Proactive's CEO Sessions.
Intermin Resources [JOHN TO UPDATE] at Proactive's Spotlight CEO Sessions
Find out more from Jon Price at Proactive's CEO Spotlight Sessions.
Proteomics International Laboratories to bring PromarkerD to Asia
Proteomics is a global leader in predictive diagnostics.
Proteomics International Laboratories raises funds for diabetic kidney test
Proteomics International Laboratories (ASX:PIQ) has raised $574,500 at $0.24 per share via a share purchase plan to existing shareholders.
Proteomics International Laboratories Ltd to raise cash
Proteomics International Laboratories Ltd (ASX:PIQ) has been granted a trading halt by the ASX this morning, pending details of a capital raising.
Proteomics International Laboratories Ltd reaches milestone for test kit
Proteomics International Laboratories Ltd (ASX:PIQ) has reached a strategic milestone in its commercialisation pathway for PromarkerD, a predictive test kit for diabetic kidney disease.
Proteomics International Laboratories Ltd grows revenue by 60%
Growth is being driven by the generic protein drug market as the sector seeks to replicate the multiple billion dollar drugs that are coming off patent.
Proteomics International Laboratories Ltd expands into key Indian market
PILL has already operated successfully in India since 2004, and therefore can build on this established exposure. The company will target this rapidly growing global biotech hub forecast to be worth $US100 billion by 2025.
Proteomics International Laboratories Ltd to utilise disruptive drug technology
Therapeutic Drug Discovery is one of PILL’s core business areas and is a major growth market. The company is specifically targeting the discovery of new analgesic (painkilling) and antibiotics compounds and will test 50 - 100 venoms i
Proteomics enhances cash reserves as global marketing drive continues
Proteomics International Laboratories has received an R&D tax incentive as a global push to commercialise company products gains traction.
ASX remained flat but this medical stock kept climbing
The Australian All Ordinaries closed flat today at 5,295 points despite the Australian Bureau of Statistics posting international trade balance figures that revealed higher exports and the narrowest trade deficit since March for the local e
Proteomics eyes Asian markets as medical test gains global exposure
Proteomics International Laboratories leadership is following up recent recognition of its global marketing achievements with a string of international engagements and a special emphasis on Asian markets.
Proteomics shares climb on granted U.S. patent for diagnostic test
The patent is a critical milestone in the development of the Diagnostic Test for Diabetic Kidney Disease in the world’s largest health care market. Investors have responded to the patent.
All Ords in low gear but this biotech play is racing
The Australian All Ordinaries closed flat at 5,305 points today, with most sectors finishing slightly in the red.
Proteomics lauded for global biotech marketing prowess
Proteomics International Laboratories reinforced its investment case Friday by taking home an industry award for outstanding international success in the medical, healthcare, and biotechnology fields.
Proteomics marks traction on a global scale
Proteomics is pressing forward with multiple major upside opportunities as a key health test internationalises and an options issue unfolds. The company’s proteomics-based technology platform is developing next-generation diagnostic t
Proteomics has world first predictive test for diabetic kidney disease
The ground breaking predictive test for diabetic kidney disease is a world first and could see "big pharma" taking a firm interest in Proteomics', with no available test for predicting the onset of kidney disease.